

To: benzconsort-oc@listserve.api.org <benzconsort-oc@listserve.api.org>
From: Bruce Jarnot <jarnotb@api.org>
Cc:
Bcc:
Received Date: 2003-11-20 19:58:29 GMT
Subject: For BHRC-OC Action: Topic of Dr. Brody's resignation

Benzene Health Research Consortium (BHRC) Oversight Committee -

Responding to Patrick's suggestion, I would like to poll the Oversight Committee on the topic of Baruch Brody's resignation...

- 1) Should this topic be added to the Dec 15 conference call agenda, or
- 2) Should the Oversight Committee convene a conference call sooner to discuss this topic?

Notes on this choice...

- No issues are presently being worked by the ERP;
- There are no issues scheduled for ERP consideration before Dec 15;
- The ERP will next be asked to consider protocol & consent form changes for Control HIV testing (CC study) and SPMA analyses (ME study).

Also per Patrick's note, the ERP has been advised of Baruch's resignation and their preferred course of action solicited, in order to carry forward their opinion to the Oversight Committee (see attached email).

If you would prefer an earlier call, please advise your availability during the weeks of Dec 01 and Dec 08, as Consortium availability may be limited next week (11/24-28) due to extended Thanksgiving vacations.

Thank you in advance for your quick reply!

Best Regards - Bruce.

Bruce M. Jarnot, Ph.D., DABT
American Petroleum Institute
Regulatory and Scientific Affairs
1220 L Street, NW (Suite 900)
Washington, DC 20005-4070
phone: (202) 682-8473 fax: -8031
email: jarnotb@api.org

-----Original Message-----

From: Bruce Jarnot
Sent: Thursday, November 20, 2003 2:32 PM
To: 'benzene-erp@listserve.api.org'
Cc: Patrick Beatty (E-mail); Stuart Cagen (E-mail)
Subject: Shanghai ERP - Baruch Brody has resigned due to ill health

Benzene Health Research Consortium (BHRC) Ethics Review Panel -

Baruch Brody today resigned from the Shanghai Health Study, stating "i have been very ill and have developed esrd [end-stage renal disease] and that precludes extensive out of town work. good luck on the remainder of the project - bab".

I would like to solicit the ERP's preferred course of action, in order to carry your collective opinion forward to the Consortium Oversight Committee...

1) Should a replacement US ethicist be recruited, maintaining original regional balance (Europe, China & US) and panel membership, and vote a new Chair? If so, can you identify a candidate ethicist for recruitment?

2) Or, should the ERP remain an independent, 2-member panel and vote a new Chair?

3) Or, given that the most active phase of ethics review was at the front-end of this study, and now that the work load on both ethics and scientific review panels has moderated, should the external panels integrate under the leadership of Jerry Rice? Both groups worked well together in this fashion at the August Asilomar meeting, and "topic lead" can be deferred to members having that specific expertise - with ethicists working ethics issues, as currently done within the science review panel for issues regarding biostatistics, molecular markers, industrial hygiene and other specialties.

Best Regards - Bruce.

Bruce M. Jarnot, Ph.D., DABT
American Petroleum Institute
Regulatory and Scientific Affairs
1220 L Street, NW (Suite 900)
Washington, DC 20005-4070
phone: (202) 682-8473 fax: -8031
email: jarnotb@api.org
